Autor(es):
Silva, Clovis A. A. ; Hilario, Maria O. ; Febronio, Marilia V. ; Oliveira, Sheila K. ; Almeida, Rozana G. ; Fonseca, Adriana R. ; Yamashita, Edson M. ; Ronchezel, Marcos V. ; Campos, Luciene L. ; Appenzeller, Simone ; Quintero, Maria V. ; Santos, Ana B. ; Medeiros, Ana C. ; Carvalho, Luciana M. ; Robazzi, Teresa C. ; Cardin, Silvana P. ; Bonfa, Eloisa
Data: 2022
Identificador Persistente: http://hdl.handle.net/11449/219463
Origem: Oasisbr
Assunto(s): Adolescent; Cyclophosphamide; Fetal loss; Outcome; Pregnancy; Systemic lupus erythematosus
Descrição
Made available in DSpace on 2022-04-28T18:55:44Z (GMT). No. of bitstreams: 0 Previous issue date: 2008-07-01
Objective. To determine pregnancy outcome and fetal loss risk factors in patients with juvenile systemic lupus erythematosus (JSLE). Methods. A total of 315 female patients with JSLE followed in 12 Brazilian pediatric rheumatology centers were consecutively selected. Menarche was observed in 298 (94.6%) patients. Patients' medical records were reviewed for pregnancy outcomes and demographic, clinical, and therapeutic data. Results. A total of 24 unplanned pregnancies occurred in 298 (8%) patients. The outcomes were 5 (21%) early fetal losses (prior to 16 wks gestation), 18 (75%) live births, and 1 (4%) death due to preeclampsia and premature birth. The frequencies of active diffuse proliferative glomerulonephritis, proteinuria ≥ 0.5 g/day, and arterial hypertension at the beginning of pregnancy were higher in pregnancies resulting in fetal losses than in live births [60% vs 5% (p = 0.02), 60% vs 5% (p = 0.02). 60% vs 5% (p = 0.02), respectively]. JSLE pregnancies with fetal losses had a significantly higher mean SLE Disease Activity Index 2000 (SLEDAI-2K) at the start of pregnancy compared with those with live births (9.40 ± 7.47 vs 3.94 ± 6.00; p = 0.049). Four pregnancies were inadvertently exposed to intravenous cyclophosphamide therapy for renal involvement despite contraceptive prescriptions, resulting in fetal loss in 3 (p = 0.02). In multivariate analysis only intravenous cyclophosphamide use at start of pregnancy (OR 25.50, 95% CI 1.72-377.93, p = 0.019) remained as an independent risk factor for fetal loss. Conclusion. We identified immunosuppressive therapy as the major contributing factor for fetal loss in JSLE, reinforcing the importance of contraception.
Paediatric Rheumatology Unit University of São Paulo
Paediatric Rheumatology Unit Federal University of São Paulo
Paediatric Rheumatology Unit Federal University of Rio de Janeiro
Paediatric Rheumatology Unit Santa Casa of São Paulo
Paediatric Rheumatology Unit State University of Rio de Janeiro
Paediatric Rheumatology Unit State University of Campinas
Paediatric Rheumatology Unit Santa Casa of Belo Horizonte
Division of Rheumatology Federal University of Rio de Janeiro
Division of Rheumatology University of São Paulo
University of São Paulo-Ribeirão Preto
Hospital São Rafael-Bahia
State University of São Paulo-Botucatu
